- Dendritic Cells (DC) Cancer Vaccines,
- Recombinant Cancer Vaccines,
- Antigen/Adjuvant Cancer Vaccines,
- Viral Vector & DNA Cancer Vaccines
Cancer Vaccines Market is valued at USD 4.5 billion in 2022 and is poised to grow at a CAGR of 14.1% from 2023 to 2029. The global market provides a detailed overview of the Cancer Vaccines Market, which has been segmented by vaccine type, indication, and application. The cancer vaccines market has been segmented by vaccine type into Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Viral Vector & DNA Cancer Vaccines. The Recombinant Cancer Vaccines segment is likely the largest and fastest-growing in terms of vaccine types. The cancer vaccines market has been segmented into Prostate Cancer, Cervical Cancer, and Others. The Cervical Cancer segment gains the maximum revenue share in 2022-2028. The cancer vaccines are segmented on application into Preventive Vaccine and Therapeutic Vaccine. According to precision business insights, the Preventive Vaccine segment is predicted to register the fastest growth rate during the forecast period.
Cancer Vaccines Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
14.1%
Largest Market
Asia Pacific
Fastest Growing Market
North America
Cancer Vaccines Market Dynamics
The increasing number of cancer cases, rising investments, government support in cancer vaccine development, and technological advancements in cancer vaccine development are the factors driving the market's expansion.
North-America Got Significant Share
Cancer Vaccines Market Regional Analysis
The North America market is expected to witness the most significant market share during the forecast period.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The cancer vaccines market report provides granular level information about the market size, regional market share, historic market (2018-2022) and forecast (2023-2029)
- The cancer vaccines market report covers in-detail insights about the competitors overview, company share analysis, key market developments, and their key strategies
- The cancer vaccines market report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The cancer vaccines market report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The cancer vaccines market report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Cancer Vaccines Market Segmentation
By Vaccine Type
By Indication Type
- Prostate Cancer,
- Cervical Cancer,
- Others
By Application
- Preventive Vaccine,
- Therapeutic Vaccine
Frequently Asked Questions
The cancer vaccines market is projected to expand at a CAGR of 14.1% during the forecast period.
The cancer vaccines market players are CSL Limited, ADURO BIOTECH INC., Astellas Pharma Inc., Merck & Co., Inc., Sanofi, Bristol-Myers Squibb Company, GlaxoSmithKline Plc., Dendreon, ASTRAZENECA PLC., and OSE Immunotherapeutics.
North America is the fastest-growing region for cancer vaccines market
| 1. Executive Summary |
| 2. Global Cancer Vaccines Market Introduction |
| 2.1. Global Cancer Vaccines Market - Taxonomy |
| 2.2. Global Cancer Vaccines Market -Definitions |
| 2.2.1. Vaccine Type |
| 2.2.2. Indication |
| 2.2.3. Application |
| 2.2.4. Region |
| 3. Global Cancer Vaccines Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Current Trends |
| 3.5. Global Cancer Vaccines Market Dynamic Factors - Impact Analysis |
| 3.6. Mergers, Acquisitions, and Collaborations |
| 4. Global Cancer Vaccines Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Cancer Vaccines Market, By Vaccine Type, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.1. Dendritic Cells (DC) Cancer Vaccines |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Recombinant Cancer Vaccines |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Antigen/Adjuvant Cancer Vaccines |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Viral Vector & DNA Cancer Vaccines |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6. Global Cancer Vaccines Market, By Indication, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1. Prostate Cancer |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Cervical Cancer |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Others |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7. Global Cancer Vaccines Market, By Application, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.1. Preventive Vaccine |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Therapeutic Vaccine |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 8. Global Cancer Vaccines Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific |
| 8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Latin America |
| 8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. MEA |
| 8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 8.6. Global Cancer Vaccines Market - Opportunity Analysis Index, By Vaccine Type, Indication, Application, and Country, 2023 - 2029 |
| 9. North America Cancer Vaccines Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 9.1. Vaccine Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Dendritic Cells (DC) Cancer Vaccines |
| 9.1.2. Recombinant Cancer Vaccines |
| 9.1.3. Antigen/Adjuvant Cancer Vaccines |
| 9.1.4. Viral Vector & DNA Cancer Vaccines |
| 9.2. Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1. Prostate Cancer |
| 9.2.2. Cervical Cancer |
| 9.2.3. Others |
| 9.3. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1. Preventive Vaccine |
| 9.3.2. Therapeutic Vaccine |
| 9.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1. United States |
| 9.4.2. Canada |
| 9.5. North America Cancer Vaccines Market - Opportunity Analysis Index, By Vaccine Type, Indication, Application, 2016-2027 |
| 9.6. North America Cancer Vaccines Market Dynamics - Trends |
| 10. Europe Cancer Vaccines Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 10.1. Vaccine Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Dendritic Cells (DC) Cancer Vaccines |
| 10.1.2. Recombinant Cancer Vaccines |
| 10.1.3. Antigen/Adjuvant Cancer Vaccines |
| 10.1.4. Viral Vector & DNA Cancer Vaccines |
| 10.2. Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Prostate Cancer |
| 10.2.2. Cervical Cancer |
| 10.2.3. Others |
| 10.3. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1. Preventive Vaccine |
| 10.3.2. Therapeutic Vaccine |
| 10.4. Country Level Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1. UK |
| 10.4.2. Germany |
| 10.4.3. France |
| 10.4.4. Italy |
| 10.4.5. Spain |
| 10.4.6. Rest of Europe |
| 10.5. Europe Cancer Vaccines Market - Opportunity Analysis Index, By Vaccine Type, Indication, Application, 2016-2027 |
| 10.6. Europe Cancer Vaccines Market Dynamics - Trends |
| 11. Asia Pacific Cancer Vaccines Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 11.1. Vaccine Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Dendritic Cells (DC) Cancer Vaccines |
| 11.1.2. Recombinant Cancer Vaccines |
| 11.1.3. Antigen/Adjuvant Cancer Vaccines |
| 11.1.4. Viral Vector & DNA Cancer Vaccines |
| 11.2. Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Prostate Cancer |
| 11.2.2. Cervical Cancer |
| 11.2.3. Others |
| 11.3. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1. Preventive Vaccine |
| 11.3.2. Therapeutic Vaccine |
| 11.4. Country Level Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1. China |
| 11.4.2. India |
| 11.4.3. ANZ |
| 11.4.4. Japan |
| 11.4.5. Rest of APAC |
| 11.5. Asia Pacific Cancer Vaccines Market - Opportunity Analysis Index, By Vaccine Type, Indication, Application, 2016-2027 |
| 11.6. Asia Pacific Cancer Vaccines Market Dynamics - Trends |
| 12. MEA Cancer Vaccines Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 12.1. Vaccine Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Dendritic Cells (DC) Cancer Vaccines |
| 12.1.2. Recombinant Cancer Vaccines |
| 12.1.3. Antigen/Adjuvant Cancer Vaccines |
| 12.1.4. Viral Vector & DNA Cancer Vaccines |
| 12.2. Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1. Prostate Cancer |
| 12.2.2. Cervical Cancer |
| 12.2.3. Others |
| 12.3. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1. Preventive Vaccine |
| 12.3.2. Therapeutic Vaccine |
| 12.4. Country Level Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1. GCC Countries |
| 12.4.2. South Africa |
| 12.4.3. Rest of MEA |
| 12.5. MEA Cancer Vaccines Market - Opportunity Analysis Index, By Vaccine Type, Indication, Application, 2016-2027 |
| 12.6. MEA Cancer Vaccines Market Dynamics - Trends |
| 13. Latin America Cancer Vaccines Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 13.1. Vaccine Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1. Dendritic Cells (DC) Cancer Vaccines |
| 13.1.2. Recombinant Cancer Vaccines |
| 13.1.3. Antigen/Adjuvant Cancer Vaccines |
| 13.1.4. Viral Vector & DNA Cancer Vaccines |
| 13.2. Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1. Prostate Cancer |
| 13.2.2. Cervical Cancer |
| 13.2.3. Others |
| 13.3. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1. Preventive Vaccine |
| 13.3.2. Therapeutic Vaccine |
| 13.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1. Brazil |
| 13.4.2. Mexico |
| 13.4.3. Argentina |
| 13.4.4. Rest of LA |
| 13.5. Latin America Cancer Vaccines Market - Opportunity Analysis Index, By Vaccine Type, Indication, Application, 2016-2027 |
| 13.6. Latin America Cancer Vaccines Market Dynamics - Trends |
| 14. Competition Landscape |
| 14.1. Strategic Dashboard of Top Market Players |
| 14.2. Company Profiles (Introduction, Financial Analysis, Product Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 14.2.1. Anixa Biosciences Inc. |
| 14.2.2. Dynavax Technologies Corporation |
| 14.2.3. Vaccinogen, Inc. |
| 14.2.4. Astrazeneca plc |
| 14.2.5. Moderna Inc. |
| 14.2.6. Vaccitech Limited |
| 14.2.7. F Hoffmann-La Roche AG |
| 14.2.8. GlaxoSmithKline PLC |
| 14.2.9. Sanofi SA |
| 14.2.10. Dendreon Pharmaceuticals LLC |
| 15. Research Methodology |
| 16. Key Assumptions and Acronyms |
- Anixa Biosciences Inc.
- Dynavax Technologies Corporation
- Vaccinogen, Inc.
- Astrazeneca plc
- Moderna Inc.
- Vaccitech Limited
- F Hoffmann-La Roche AG
- GlaxoSmithKline PLC
- Sanofi SA
- Dendreon Pharmaceuticals LLC